Wim J. Kirkels

7.9k total citations · 1 hit paper
97 papers, 5.8k citations indexed

About

Wim J. Kirkels is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Wim J. Kirkels has authored 97 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Surgery, 46 papers in Pulmonary and Respiratory Medicine and 27 papers in Oncology. Recurrent topics in Wim J. Kirkels's work include Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Diagnosis and Treatment (37 papers) and Prostate Cancer Treatment and Research (27 papers). Wim J. Kirkels is often cited by papers focused on Bladder and Urothelial Cancer Treatments (41 papers), Prostate Cancer Diagnosis and Treatment (37 papers) and Prostate Cancer Treatment and Research (27 papers). Wim J. Kirkels collaborates with scholars based in Netherlands, United States and Canada. Wim J. Kirkels's co-authors include Fritz H. Schröder, Ellen C. Zwarthoff, Theodorus van der Kwast, Harry J. de Koning, Marie‐Louise Essink‐Bot, Monique J. Roobol, Wim C.J. Hop, Jackie Bosch, Bas W.G. van Rhijn and François Radvanyi and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Wim J. Kirkels

95 papers receiving 5.6k citations

Hit Papers

EORTC Nomograms and Risk Groups for Predicting Recurrence... 2015 2026 2018 2022 2015 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin
    2015 444 citations Wim J. Kirkels et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wim J. Kirkels Netherlands 43 3.4k 2.6k 1.3k 1.1k 1.1k 97 5.8k
Daniel A. Barocas United States 48 3.4k 1.0× 3.6k 1.4× 1.4k 1.0× 718 0.7× 1.5k 1.4× 210 7.2k
Ofer Yossepowitch Israel 35 1.8k 0.5× 3.4k 1.3× 608 0.5× 787 0.7× 740 0.7× 164 5.0k
David C. Miller United States 41 2.4k 0.7× 4.7k 1.8× 1.3k 1.0× 2.2k 2.0× 707 0.7× 181 6.8k
Claudio Jeldres Canada 50 3.7k 1.1× 4.8k 1.9× 1.5k 1.1× 1.8k 1.6× 1.0k 1.0× 221 7.7k
Matthew J. Resnick United States 32 1.8k 0.5× 2.2k 0.8× 984 0.7× 405 0.4× 771 0.7× 117 4.3k
Gary Lieskovsky United States 50 7.6k 2.2× 2.9k 1.2× 1.4k 1.0× 765 0.7× 4.0k 3.8× 163 10.2k
S. Machele Donat United States 55 7.3k 2.2× 1.9k 0.7× 1.3k 0.9× 711 0.6× 3.5k 3.3× 175 8.8k
Mirja Ruutu Finland 26 1.2k 0.3× 2.8k 1.1× 950 0.7× 435 0.4× 787 0.7× 111 4.3k
Marc Zerbib France 34 2.0k 0.6× 2.3k 0.9× 776 0.6× 862 0.8× 880 0.8× 262 4.7k
Stephanie Daignault United States 36 1.7k 0.5× 2.5k 1.0× 1.2k 0.9× 2.0k 1.8× 582 0.6× 123 5.1k

Countries citing papers authored by Wim J. Kirkels

Since Specialization
Citations

This map shows the geographic impact of Wim J. Kirkels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim J. Kirkels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim J. Kirkels more than expected).

Fields of papers citing papers by Wim J. Kirkels

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim J. Kirkels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim J. Kirkels. The network helps show where Wim J. Kirkels may publish in the future.

Co-authorship network of co-authors of Wim J. Kirkels

This figure shows the co-authorship network connecting the top 25 collaborators of Wim J. Kirkels. A scholar is included among the top collaborators of Wim J. Kirkels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim J. Kirkels. Wim J. Kirkels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rhijn, Bas W.G. van, Mireía Musquera, Liyang Liu, et al.. (2014). Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. Modern Pathology. 28(5). 695–705. 33 indexed citations
3.
Roobol, Monique J., Ries Kranse, Chris H. Bangma, et al.. (2013). Screening for Prostate Cancer: Results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer. European Urology. 64(4). 530–539. 91 indexed citations
4.
Zuiverloon, Tahlita C.M., et al.. (2011). Markers Predicting Response to Bacillus Calmette-Guérin Immunotherapy in High-Risk Bladder Cancer Patients: A Systematic Review. European Urology. 61(1). 128–145. 142 indexed citations
5.
6.
Vledder, Mark G. van, Jos A. van der Hage, Wim J. Kirkels, et al.. (2010). Cervical Lymph Node Dissection for Metastatic Testicular Cancer. Annals of Surgical Oncology. 17(6). 1682–1687. 21 indexed citations
7.
Korfage, Ida J., Monique J. Roobol, Harry J. de Koning, et al.. (2008). Does “Normal” Aging Imply Urinary, Bowel, and Erectile Dysfunction? A General Population Survey. Urology. 72(1). 3–9. 37 indexed citations
8.
Kompier, Lucie C., Irene Lurkin, Marcel Vermeij, et al.. (2008). The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. The Journal of Pathology. 218(1). 104–112. 39 indexed citations
9.
Vermaas, Maarten, Floris Ferenschild, Cornelis Verhoef, et al.. (2006). Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer. European Journal of Surgical Oncology. 33(4). 452–458. 100 indexed citations
10.
Lind, May Y., Eric J. Hazebroek, Wim J. Kirkels, et al.. (2004). Laparoscopic versus open donor nephrectomy: ureteral complications in recipients. Urology. 63(1). 36–39. 15 indexed citations
11.
Rhijn, Bas W.G. van, Irene Lurkin, Dominique Chopin, et al.. (2003). Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.. PubMed. 9(1). 257–63. 65 indexed citations
12.
Korfage, Ida J., Marie‐Louise Essink‐Bot, Joanna B. Madalinska, et al.. (2003). Measuring disease specific quality of life in localized prostate cancer: The Dutch experience. Quality of Life Research. 12(4). 459–464. 31 indexed citations
13.
Madalinska, Joanna B., Marie‐Louise Essink‐Bot, Harry J. de Koning, et al.. (2001). Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. The Prostate. 46(2). 87–97. 34 indexed citations
14.
Kranse, Ries, et al.. (1999). The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update. European Urology. 35(5-6). 539–543. 58 indexed citations
15.
Steyerberg, Ewout W., A. Gerl, S.D. Fosså, et al.. (1998). Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer.. Journal of Clinical Oncology. 16(1). 269–274. 72 indexed citations
16.
Essink‐Bot, Marie‐Louise, Harry J. de Koning, H. G. T. Nijs, et al.. (1998). Short-Term Effects of Population-Based Screening for Prostate Cancer on Health-Related Quality of Life. JNCI Journal of the National Cancer Institute. 90(12). 925–931. 130 indexed citations
17.
Petrovich, Zbigniew, Luc Baert, Malcolm A. Bagshaw, et al.. (1997). Adenocarcinoma of the Prostate: Innovations in Management. American Journal of Clinical Oncology. 20(2). 111–119. 20 indexed citations
18.
Kirkels, Wim J. & John Rietbergen. (1997). Screening for prostate cancer. Urological Research. 25(S2). S53–S56. 7 indexed citations
19.
Damhuis, Ronald, et al.. (1996). European randomized study of screening for prostate cancer—The Rotterdam pilot studies. International Journal of Cancer. 65(2). 145–151. 56 indexed citations
20.
Gaast, Ate van der, Wim J. Kirkels, B. G. Blijenberg, & Ted A.W. Splinter. (1992). Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract. Journal of Cancer Research and Clinical Oncology. 118(8). 626–628. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel A. Barocas Breakdown of academic impact, for papers by Ofer Yossepowitch Breakdown of academic impact, for papers by David C. Miller Breakdown of academic impact, for papers by Claudio Jeldres Breakdown of academic impact, for papers by Matthew J. Resnick Breakdown of academic impact, for papers by Gary Lieskovsky Breakdown of academic impact, for papers by S. Machele Donat Breakdown of academic impact, for papers by Mirja Ruutu Breakdown of academic impact, for papers by Marc Zerbib Breakdown of academic impact, for papers by Stephanie Daignault
Rankless by CCL
2026